- Country: USA
- Summary: Advanced Development And Validation Of Emerging Biospecimen Science Technologies For Basic And Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- UST Ref No: 111927910
- Deadline: 03 Oct 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: USD 300000
- Notice Type: Tender
- Document Ref. No.: RFA-CA-25-004
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Through This Notice Of Funding Opportunity (Nofo), National Cancer Institute (Nci) Solicits Grant Applications Proposing Exploratory Research Projects Focused On Further Development And Validation Of Emerging Technologies That Improve The Quality And Handling Of Samples Used For Cancer Research Or Clinical Care. Through This Nofo, Nci Will Support The Development Of Tools, Devices, Assays, And Associated Methods For The Collection, Handling, Processing, Preservation, Or Storage Of Cancer-Relevant Biospecimens And Their Derivatives. This Includes Tools With New Capabilities To Preserve Or Protect Sample Integrity, Or Establish Verification Criteria For Quality Assessment/Quality Control And Address Issues Related To Pre-Analytical Degradation Of Of Targeted Analytes. Major Feasibility Gaps For The Technology Or Methodology Should Have Already Been Overcome, As Demonstrated By Supportive Preliminary Data, But The Tool Requires Further Development And Rigorous Validation. These Technologies Are Expected To Accelerate And/Or Enhance Research In Cancer Biology, Early Detection And Screening, Clinical Diagnosis, Treatment, Or Epidemiology And/Or Address Issues Associated With Cancer Health Disparities. This Funding Opportunity Is Part Of A Broader Nci-Sponsored Innovative Molecular Analysis Technologies (Imat) Program.
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINAdvanced Development And Validation Of Emerging Biospecimen Science Technologies For Basic And Clinical Cancer Research (R33 Clinical Trial Not Allowed) - USA Tender
The NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for Advanced Development And Validation Of Emerging Biospecimen Science Technologies For Basic And Clinical Cancer Research (R33 Clinical Trial Not Allowed). This tender is published on USARFP under UST Ref No: 111927910 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-10-03.
The estimated tender value is USD 300000, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
